There are many impediments to the progress of clinical and medical genetics in developing countries. Higher priorities concerning basic health care usually take precedence over genetic diseases and birth defects among medical professionals and public health officials. This is so in spite of the fact that the global prevalence of these conditions seems higher than in the developed world and that limited resources enhance the burden on individuals, families and populations. Furthermore, as a consequence of recent advances in medical genetics, demand for genetic services has increased, reinforcing the need for programs for the management and prevention of genetic diseases and birth defects, especially at primary health care level. An overview of these issues in Brazil is presented here, with information on the health system, the evolution of medical and clinical genetics in the country, and the situation of medical and clinical genetic services. We discuss proposals for implementing appropriate, ethically acceptable and equitable clinical genetic services for the Brazilian population.

Keywords:
Birth defects, Brazil, Clinical genetics, Community genetics, Developing countries, Genetic diseases, Genetic services
1.
World Health Organization: Human Genetics Programme, 2002: Collaboration in Medical Genetics. WHO/HGN/WG/02.2 2002.
2.
World Health Organization: Human Genetics, 1999. Services for the prevention and management of genetic disorders and birth defects in developing countries. Report of a joint WHO/WAOPBD meeting. WHO/HGN/GL/WAOPBD/99.1 1999.
3.
UNICEF: The State of the World’s Children 2003. New York, UNICEF, 2002.
4.
World Health Organization: Human Genetics Programme 2000: Primary health care approaches for prevention and control of congenital and genetic disorders. WHO/HGN/WG/00.1 1999.
5.
World Health Organization: Human Genetics Programme 2001: Review of ethical issues in medical genetics. WHO/HGN/ETH/00.4 2001.
6.
Christianson AL: Medical genetics in primary health care. Indian J Pediatr 2000;67:831–835.
7.
Alwan A, Modell B: Community Control of Genetic and Congenital Disorders. EMRO Technical Publications Series 24. Alexandria, WHO Eastern Mediterranean Regional Office, 1997.
8.
Christianson AL, Venter PA, Modiba JH, Nelson MM: Development of a primary health care clinical genetic service in rural South Africa – The Northern Province experience, 1990–1996. Community Genet 2000;3:77–84.
9.
Castilla EE, Orioli IM: ECLAMC: The Latin-American Collaborative Study of Congenital Malformations. Community Genet 2004;7:76–94.
10.
World Health Organization: Human Genetics Programme 1998:Medical genetic services in Latin American. WHO/HGN/CONS/MGS/98.4 1998.
11.
Brunoni D: Estado atual do desenvolvimento dos serviços de genética médica no Brasil. Genet Mol Biol 1997;20(suppl 1):11–23.
12.
IBGE – Fundação Instituto Brasileiro de Geografia e Estatística; 2002. http://www.ibge.gov.br/brasil_em_sintese/tabelas/.
13.
IBGE – Fundação Instituto Brasileiro de Geografia e Estatística; Censo Demográfico 2000. http://www.ibge.gov.br.
14.
DATASUS – Ministério da Saúde. http://www.datasus.gov.br.
15.
Carvalho-Silva DR, Santos FR, Rocha J, Pena SD: The phylogeography of Brazilian Y-chromosome lineages. Am J Hum Genet 2001;68:281–286.
16.
United Nations: Special Session on Children. National Reports. Report of the Federative Republic of Brazil on the Attainment of the Goals Set at the World Summit for Children. September, 2001. http://www.unicef.org/specialsession/how_country/.
17.
United Nations Development Programme (UNDP): Human Development Report, 2003. http://www.undp.org/hdr2003/.
18.
Victora CS, Barros FC: Infant mortality due to perinatal causes in Brazil: Trends, regional patterns and possible interventions. São Paulo Med J 2001;119:33–42.
19.
Conselho Federal de Medicina, 2004. http://www.portalmedico.org.br.
20.
Senado Federal – Constituição da República Federativa do Brasil, 1988. Imprensa Oficial do Estado S.A. IMESP, 1988.
21.
Castilla EE: Impact of congenital malformations on public health. Situation in South America. Front Fetal Health 2000;2:15–16.
22.
Pinto LIB, Paskulin GA, Graziadio C, Mendez HMM: The frequency of genetic diseases in a high risk ward in a pediatric hospital. Braz J Genet 1996;19:145–149.
23.
Salzano FM: Public health in the First and Third Worlds: Challenges and perspectives. Ciência Saúde Coletiva 2002;7:7–16.
24.
Roisenberg I: Hemofilia e estados hemofilóides no Rio grande do Sul: Refqüência, fisiologia e herança. Universidade Federal do Rio Grande do Sul, Departamento de Genética, Publicação No 1, 1971.
25.
Buchalter MS, Wanmacher CMD, Wajner M: Tay-Sachs disease: Screening and prevention program in Porto Alegre. Rev Bras Genet 1983;6:539–547.
26.
Azevedo WC, Silva MLF, Grasse CB, Azevêdo ES: Deficiência de glicose-6-fosfato desidrogenase em pacientes de um hospital de Salvador, Bahia, Brasil. Rev Brasil Pesquisas Méd Biol 1978;11:49–52.
27.
Sena LLA, Ramalho AS: Clinical evaluation of glucose-6-phosphate dehydrogenase deficiency in a Brazilian population. Rev Bras Genet 1985;8:89–96.
28.
Saad STO, Salles TSI, Carvalho MHM, Costa FF: Molecular characterization of glucose-6-phosphate dehydrogenase in Brazil. Hum Heredity 1997;47:17–21.
29.
Arruda VR, Siqueira LH, Gonçalves MS, Von Zuben PM, Soares MCP, Menezes R, Annichino-Bizzacchi JM, Costa FF: Prevalence of the mutation C677→T in the methylene tetrahydrofolate reductase gene among distinct ethnic groups in Brazil. Am J Med Genet 1998;78:332–335.
30.
Sartorato EL, Gottardi E, Oliveira CA, Magna LA, Annichino-Bizzachi JM, Seixas CA, Maciel-Guerra AT: Determination of the frequency of 35delG allele in Brazilian neonates. Clin Genet 2000;58:339–340.
31.
Freire-Maia N, Pinheiro M: Ectodermal Dysplasias: A Clinical and Genetic Study. New York, Liss, 1985.
32.
Quelce-Salgado A: A new type of dwarfism with various bone aplasias and hypoplasias of the extremities. Acta Genet Stat Med 1964;14:63–66.
33.
Freire-Maia A: Genetics of acheiropodia (the handless and footless families of Brazil). Clin Genet 1975;7:98–102.
34.
Lopes-Cendes I, Teive HG, Calcagnotto ME, Da Costa JC, Cardoso F, Viana E, et al: Frequency of the different mutations causing spinocerebellar ataxia (SCA1, SCA2, MJD/SCA3 and DRPLA) in a large group of Brazilian patients. Arq Neuropsiquiatr 1997;55:519–529.
35.
Jardim LB, Leite JCL, Silveira EL, Pereira ML, Giugliani R: Resultados preliminares de um programa de detecção precoce para aminoacidopatias no Rio Grande do Sul. J Pediatr 1992;68:189–242.
36.
Souza CFM, Schwartz I, Giugliani R: Neonatal screening of metabolic disorders. Ciência Saúde Coletiva 2002;7:129–137.
37.
Ministério da Saúde: Programa Nacional de Triagem Neonatal; in: Reduzindo as Desigualdades e Ampliando o Acesso à Assistência à Saúde no Brasil 1998–2002. Série G. Estatística e Informação em Saúde. Brasília, Ministério da Saúde, Secretaria de Assistência à Saúde, 2002.
38.
Salzano FM, Tondo CV: Hemoglobin types in Brazilian populations. Hemoglobin 1982;6:85–97.
39.
Ramalho AS: As Hemoglobinopatias Hereditárias: Um Problema de Saúde Pública no Brasil. Ribeirão Preto, Sociedade Brasileira de Genética/Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), 1986.
40.
Zago MA, Costa FF: Hereditary haemoglobin disorders in Brazil. Trans R Soc Trop Med Hyg 1985;79:385–388.
41.
Naoum PC, Isiqui WD, Pagotto RR, Domingos CRB: Prevalência de hemoglobinopatias em amostras de proveniência diferenciada. Bol Soc Bras Hematol Hemoter 1989;11;69–72.
42.
Teixeira RC, Ramalho AS: Genetics and public health: Response of a Brazilian population to an optional Hemoglobinopathy Program. Braz J Genet 1994;17:435–438.
43.
Serra HG, Martins CSB, Silva RBP, Ramalho AS: Evaluation of genetic counseling offered to Brazilian carriers of the beta-thalassemia trait and their relatives. Braz J Genet 1995;18:479–484.
44.
Ministério da Saúde: Gabinete do Ministro. Portaria GM/No 822, de 6 de junho de 2001. Diário Oficial 2001;111:Seção 1.
45.
Ramalho AS, Magna LA, Paiva-e-Silva RB: Government directive MS 822/01: Unique aspects of hemoglobinopathies on public health in Brazil. Cad Saúde Pública 2003;19:1195–1199.
46.
Carothers AD, Castilla EE, Dutra MG, Hook EB: Search for ethnic, geographic, and other factors in the epidemiology of Down syndrome in South America: Analysis of data from the ECLAMC project. Am J Med Genet. 2001;103:149–156.
47.
Borovik CL, Brunoni D, Sato AE, Barletta H, Dualibi-Casanova L, Hironaka HC, Brunoni LR, Brock R, Carvalho LA, Costa Ede C: Chromosome abnormalities in selected newborn infants with malformations in Brazil. Am J Med Genet 1989;34:320–324.
48.
Orioli I: Availability of teratogens in Brazil: Misoprostol and thalidomide. Front Fetal Health 2000;2:8–9.
49.
Gonzalez CH, Dias MJM: Congenital malformation in children exposed to misoprostol in utero. Front Fetal Health 1999;1:15.
50.
McKusick AV: Medical genetics. A 40-year perspective on the evolution of a medical specialty from a basic science. JAMA 1993;270:2351–2356.
51.
Beiguelman B: Human and medical genetics in Brazil. Genet Mol Biol 2000;23:277–281.
52.
Porciúncula CGG, Marques-de-Faria AP, Norato DYJ: O ensino de Genética nos cursos de Medicina do país. Livro de Resumos do XIV Congresso Brasileiro de Genética Clínica, 2002, p 61.
53.
Ministério da Educação: Secretaria de Educação Superior. Comissão Nacional de Residência Médica, 2004. http://www.mec.gov.br/sesu/CNRM/consultaCNRM.asp.
54.
Associação Médica Brasileira. http://www.amb.org.br.
55.
Sociedade Brasileira de Genética Clínica. http://sbgclin.org.br.
56.
Greendale K, Pyeritz RE: Empowering primary care health professionals in medical genetics: How soon? How fast? How far? Am J Med Genet 2001;106:223–232.
57.
Donnai D: Genetic services. Clin Genet 2002;61:1–6.
58.
Ramalho AS, Paiva e Silva RB, Teixeira RC, Compri MB: Haemoglobin screening: Response of a Brazilian community to optional programs. Cad Saúde Pública 1999;15:591–595.
59.
Ramalho AS, Paiva e Silva RB: Community genetics: A new discipline and its application in Brazil. Cad Saúde Pública 2000;16:261–263.
60.
Penchaszadeh VB, Christianson AL, Giugliani R, Boulyjenkov V, Katz M: Services for the prevention and management of genetic disorders and birth defects in developing countries. Community Genet 1999;2:196–201.
61.
Guttmacher AE, Jenkins F, Uhlmann WR: Genomic medicine: Who will practice it? A call to open arms. Am J Med Genet 2001;106:216–222.
62.
World Health Organization: Statement of the WHO Expert Consultation on New Development in Human Genetics, 2000. WHO/HGN/WG/00.3 2000.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.